895540-88-2Relevant academic research and scientific papers
Constructing Mononuclear Palladium Catalysts by Precoordination/Solvothermal Polymerization: Recyclable Catalyst for Regioselective Oxidative Heck Reactions
Li, Wen-Hao,Li, Cun-Yao,Xiong, Huan-Yan,Liu, Yang,Huang, Wen-Yong,Ji, Guang-Jun,Jiang, Zheng,Tang, Hai-Tao,Pan, Ying-Ming,Ding, Yun-Jie
supporting information, p. 2448 - 2453 (2019/02/03)
Heterogeneous, metal, single-site catalysts often exhibit higher catalytic performance than other catalysts because of their maximized atom efficiency of 100 %. Reported herein is a precoordination/solvothermal polymerization strategy to fabricate a stabl
Atom-economical cobalt-catalysed regioselective coupling of epoxides and aziridines with alkenes
Prina Cerai, Gabriele,Morandi, Bill
supporting information, p. 9769 - 9772 (2016/08/04)
We demonstrate that a simple cobalt complex can regioselectively couple epoxides and aziridines with alkenes to generate valuable homoallylic alcohols and amines. The intramolecular reaction exhibits complete atom economy and, in contrast to traditional Mizoroki-Heck reactions, does not require stoichiometric amounts of base. An indole derivative was also shown to be a suitable coupling partner. Finally, promising results regarding the development of an intermolecular process using both epoxides and aziridines are reported, as well as preliminary mechanistic studies suggesting a radical mechanism.
Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
-
Page/Page column 70, (2008/06/13)
The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
